Stockreport

AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trialANB020-mediated eosinophil reduction is aligned with genotyp [Read more]